CD8A and cancer: A recent meta-analysis demonstrated that high-density TILs, CD3+ TILs, CD4+ TILs, CD8+ TILs and CD20+ TILs in cancer nests were good prognostic markers for NSCLC patients (Chen et al., 2020).